Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
Background: Venous thromboembolism (VTE) is a common complication among patients
with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and …
with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and …
Guidelines for perioperative care for pancreatoduodenectomy: enhanced recovery after surgery (ERAS) recommendations 2019
Background Enhanced recovery after surgery (ERAS) pathways are now implemented
worldwide with strong evidence that adhesion to such protocol reduces medical …
worldwide with strong evidence that adhesion to such protocol reduces medical …
Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update
PURPOSE To conduct an update of the ASCO venous thromboembolism (VTE) guideline.
METHODS After publication of potentially practice-changing clinical trials, identified through …
METHODS After publication of potentially practice-changing clinical trials, identified through …
Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update
PURPOSE To provide updated recommendations about prophylaxis and treatment of
venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the …
venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the …
Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial …
AM Young, A Marshall, J Thirlwall… - Journal of Clinical …, 2018 - ascopubs.org
Purpose Venous thromboembolism (VTE) is common in patients with cancer. Long-term
daily subcutaneous low molecular weight heparin has been standard treatment for such …
daily subcutaneous low molecular weight heparin has been standard treatment for such …
[HTML][HTML] Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations—2019 update
Background This is the first updated Enhanced Recovery After Surgery (ERAS) Society
guideline presenting a consensus for optimal perioperative care in gynecologic/oncology …
guideline presenting a consensus for optimal perioperative care in gynecologic/oncology …
[HTML][HTML] Edoxaban for the treatment of cancer-associated venous thromboembolism
Background Low-molecular-weight heparin is the standard treatment for cancer-associated
venous thromboembolism. The role of treatment with direct oral anticoagulant agents is …
venous thromboembolism. The role of treatment with direct oral anticoagulant agents is …
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice …
JR Brahmer, C Lacchetti, BJ Schneider… - Journal of Clinical …, 2018 - ascopubs.org
Purpose To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events in patients treated with …
recommended management of immune-related adverse events in patients treated with …
Cancer-associated venous thromboembolism: burden, mechanisms, and management
Venous thromboembolism (VTE) is a significant health problem in the general population
but especially in cancer patients. In this review, we discuss the epidemiology and burden of …
but especially in cancer patients. In this review, we discuss the epidemiology and burden of …
[HTML][HTML] Guidelines for postoperative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations—Part II
Guidelines for postoperative care in gynecologic/oncology surgery: Enhanced Recovery After
Surgery (ERAS®) Society recommendations — Part II - ScienceDirect Skip to main contentSkip …
Surgery (ERAS®) Society recommendations — Part II - ScienceDirect Skip to main contentSkip …